| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 17 | 2025 | 248 | 4.020 |
Why?
|
| Pancreas | 7 | 2017 | 256 | 2.020 |
Why?
|
| Surgeons | 8 | 2025 | 292 | 1.980 |
Why?
|
| Pancreatitis, Chronic | 12 | 2021 | 54 | 1.960 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 7 | 2012 | 22 | 1.730 |
Why?
|
| Specialties, Surgical | 7 | 2021 | 75 | 1.610 |
Why?
|
| Surgical Procedures, Operative | 7 | 2025 | 217 | 1.540 |
Why?
|
| Islets of Langerhans Transplantation | 14 | 2021 | 247 | 1.490 |
Why?
|
| Pandemics | 14 | 2022 | 873 | 1.470 |
Why?
|
| Chlorides | 6 | 2012 | 100 | 1.450 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 338 | 1.440 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 333 | 1.440 |
Why?
|
| Pancreatectomy | 15 | 2021 | 168 | 1.320 |
Why?
|
| Digestive System Surgical Procedures | 6 | 2019 | 133 | 1.310 |
Why?
|
| Epithelial Cells | 10 | 2012 | 700 | 1.190 |
Why?
|
| Endosonography | 6 | 2020 | 100 | 1.090 |
Why?
|
| Patient Advocacy | 2 | 2025 | 63 | 1.080 |
Why?
|
| Intestinal Mucosa | 11 | 2012 | 825 | 1.050 |
Why?
|
| Periodicals as Topic | 2 | 2024 | 166 | 1.050 |
Why?
|
| Neoadjuvant Therapy | 12 | 2024 | 446 | 1.040 |
Why?
|
| Protein Kinase C | 7 | 2005 | 260 | 1.040 |
Why?
|
| Colon | 6 | 2012 | 540 | 1.030 |
Why?
|
| Education, Medical, Graduate | 8 | 2024 | 425 | 0.980 |
Why?
|
| Humans | 124 | 2025 | 93132 | 0.980 |
Why?
|
| Physician's Role | 2 | 2025 | 175 | 0.930 |
Why?
|
| Surgery Department, Hospital | 3 | 2020 | 43 | 0.910 |
Why?
|
| Quaternary Ammonium Compounds | 4 | 2007 | 81 | 0.890 |
Why?
|
| Pancreatitis, Acute Necrotizing | 4 | 2012 | 18 | 0.860 |
Why?
|
| Gastroenterostomy | 2 | 2020 | 7 | 0.790 |
Why?
|
| Infection Control | 4 | 2020 | 130 | 0.780 |
Why?
|
| Pancreatic Neoplasms | 7 | 2014 | 714 | 0.780 |
Why?
|
| Cultural Diversity | 2 | 2021 | 62 | 0.760 |
Why?
|
| Breast Neoplasms | 11 | 2024 | 3155 | 0.760 |
Why?
|
| Pancreaticoduodenectomy | 7 | 2016 | 92 | 0.720 |
Why?
|
| Patient Selection | 4 | 2020 | 688 | 0.710 |
Why?
|
| Sexism | 2 | 2021 | 56 | 0.700 |
Why?
|
| Truth Disclosure | 2 | 2021 | 73 | 0.680 |
Why?
|
| Disaster Planning | 1 | 2021 | 24 | 0.680 |
Why?
|
| Racism | 3 | 2021 | 103 | 0.660 |
Why?
|
| Personnel Selection | 1 | 2021 | 63 | 0.650 |
Why?
|
| Judgment | 1 | 2021 | 68 | 0.650 |
Why?
|
| Physicians, Women | 1 | 2021 | 58 | 0.650 |
Why?
|
| Checklist | 1 | 2021 | 73 | 0.650 |
Why?
|
| Advisory Committees | 2 | 2020 | 90 | 0.650 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2021 | 135 | 0.640 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 99 | 0.640 |
Why?
|
| Immune Tolerance | 5 | 2010 | 378 | 0.640 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 150 | 0.630 |
Why?
|
| Morals | 1 | 2021 | 102 | 0.620 |
Why?
|
| Accreditation | 1 | 2020 | 74 | 0.620 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 18 | 0.610 |
Why?
|
| Quality of Health Care | 2 | 2020 | 376 | 0.610 |
Why?
|
| United States | 25 | 2025 | 7581 | 0.600 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 56 | 0.600 |
Why?
|
| Betacoronavirus | 7 | 2020 | 283 | 0.600 |
Why?
|
| Health Resources | 1 | 2020 | 78 | 0.590 |
Why?
|
| Music | 1 | 2019 | 35 | 0.580 |
Why?
|
| Protein Kinase C-epsilon | 6 | 2010 | 22 | 0.580 |
Why?
|
| Cyclic AMP | 3 | 2010 | 275 | 0.580 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 290 | 0.580 |
Why?
|
| Surgical Wound Infection | 3 | 2019 | 236 | 0.580 |
Why?
|
| Gastric Outlet Obstruction | 2 | 2017 | 10 | 0.550 |
Why?
|
| Postoperative Complications | 9 | 2025 | 2552 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 2543 | 0.540 |
Why?
|
| Tetradecanoylphorbol Acetate | 5 | 2010 | 121 | 0.540 |
Why?
|
| Decision Making | 2 | 2020 | 671 | 0.540 |
Why?
|
| Informed Consent | 1 | 2020 | 276 | 0.530 |
Why?
|
| Pancreatitis | 4 | 2012 | 94 | 0.510 |
Why?
|
| Electronic Health Records | 1 | 2020 | 373 | 0.490 |
Why?
|
| Healthcare Disparities | 4 | 2025 | 496 | 0.480 |
Why?
|
| Spinal Cord | 1 | 2017 | 236 | 0.480 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 109 | 0.480 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 280 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 449 | 0.460 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 561 | 0.460 |
Why?
|
| Triage | 3 | 2020 | 131 | 0.440 |
Why?
|
| Internship and Residency | 7 | 2021 | 1074 | 0.440 |
Why?
|
| Career Mobility | 2 | 2025 | 37 | 0.440 |
Why?
|
| Societies, Medical | 5 | 2021 | 618 | 0.430 |
Why?
|
| Anastomotic Leak | 2 | 2014 | 109 | 0.430 |
Why?
|
| History, 20th Century | 5 | 2021 | 312 | 0.430 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2014 | 9 | 0.420 |
Why?
|
| Choristoma | 1 | 2014 | 59 | 0.410 |
Why?
|
| Pancreatic Fistula | 2 | 2011 | 17 | 0.410 |
Why?
|
| Female | 42 | 2025 | 48542 | 0.400 |
Why?
|
| Endocytosis | 3 | 2010 | 184 | 0.400 |
Why?
|
| Peer Review | 1 | 2013 | 20 | 0.400 |
Why?
|
| Transplantation, Autologous | 12 | 2021 | 359 | 0.400 |
Why?
|
| Gastrointestinal Motility | 1 | 2013 | 26 | 0.390 |
Why?
|
| Lactones | 2 | 2003 | 27 | 0.380 |
Why?
|
| Capsaicin | 1 | 2012 | 43 | 0.380 |
Why?
|
| TRPV Cation Channels | 1 | 2012 | 16 | 0.380 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 1171 | 0.380 |
Why?
|
| Cell Line | 12 | 2012 | 2458 | 0.370 |
Why?
|
| Congresses as Topic | 1 | 2013 | 121 | 0.370 |
Why?
|
| Protein Kinase C-delta | 2 | 2010 | 29 | 0.370 |
Why?
|
| Solute Carrier Family 12, Member 2 | 5 | 2012 | 16 | 0.370 |
Why?
|
| Workload | 2 | 2020 | 126 | 0.360 |
Why?
|
| Carbachol | 4 | 2005 | 34 | 0.360 |
Why?
|
| Cholangitis | 1 | 2012 | 19 | 0.360 |
Why?
|
| Choledocholithiasis | 1 | 2012 | 14 | 0.360 |
Why?
|
| Duodenal Diseases | 1 | 2012 | 25 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 147 | 0.350 |
Why?
|
| Male | 38 | 2025 | 44355 | 0.350 |
Why?
|
| Specialty Boards | 1 | 2011 | 22 | 0.350 |
Why?
|
| Laparoscopy | 4 | 2020 | 765 | 0.350 |
Why?
|
| Diverticulum | 1 | 2012 | 43 | 0.350 |
Why?
|
| Biomedical Research | 2 | 2021 | 432 | 0.350 |
Why?
|
| Clinical Competence | 3 | 2020 | 810 | 0.340 |
Why?
|
| Education, Medical | 3 | 2022 | 227 | 0.340 |
Why?
|
| Blood Glucose | 4 | 2021 | 866 | 0.330 |
Why?
|
| Colectomy | 1 | 2012 | 192 | 0.330 |
Why?
|
| Cost Savings | 1 | 2010 | 67 | 0.320 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 282 | 0.320 |
Why?
|
| Pancreatic Cyst | 1 | 2010 | 29 | 0.310 |
Why?
|
| Career Choice | 1 | 2011 | 153 | 0.310 |
Why?
|
| Gallbladder Neoplasms | 1 | 2010 | 23 | 0.310 |
Why?
|
| Bile Acids and Salts | 2 | 2011 | 77 | 0.310 |
Why?
|
| Clathrin | 1 | 2009 | 31 | 0.310 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2010 | 52 | 0.300 |
Why?
|
| Health Expenditures | 1 | 2010 | 98 | 0.300 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 215 | 0.300 |
Why?
|
| Middle Aged | 29 | 2024 | 27535 | 0.300 |
Why?
|
| Program Development | 1 | 2010 | 129 | 0.290 |
Why?
|
| Universities | 3 | 2019 | 150 | 0.290 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 191 | 0.280 |
Why?
|
| Critical Care | 3 | 2020 | 442 | 0.280 |
Why?
|
| Adult | 27 | 2024 | 27849 | 0.280 |
Why?
|
| Chicago | 4 | 2020 | 1452 | 0.270 |
Why?
|
| Trastuzumab | 6 | 2024 | 86 | 0.270 |
Why?
|
| Membrane Proteins | 3 | 2011 | 1260 | 0.270 |
Why?
|
| Potassium Channels | 3 | 2004 | 346 | 0.270 |
Why?
|
| Ultrasonography, Interventional | 2 | 2020 | 121 | 0.260 |
Why?
|
| Islets of Langerhans | 3 | 2021 | 556 | 0.260 |
Why?
|
| Drainage | 3 | 2015 | 170 | 0.260 |
Why?
|
| Intestinal Diseases | 2 | 2009 | 84 | 0.260 |
Why?
|
| Blood Proteins | 1 | 2007 | 144 | 0.260 |
Why?
|
| Muscarinic Agonists | 2 | 2005 | 22 | 0.250 |
Why?
|
| Abdominal Pain | 4 | 2021 | 143 | 0.250 |
Why?
|
| Hospital Mortality | 1 | 2009 | 480 | 0.250 |
Why?
|
| Students, Medical | 2 | 2022 | 433 | 0.250 |
Why?
|
| Immunoconjugates | 2 | 2024 | 129 | 0.250 |
Why?
|
| Carcinoma | 1 | 2010 | 439 | 0.250 |
Why?
|
| Treatment Outcome | 17 | 2024 | 9070 | 0.250 |
Why?
|
| Risk Assessment | 5 | 2020 | 2434 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 1447 | 0.240 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 2787 | 0.240 |
Why?
|
| Membrane Transport Proteins | 2 | 2005 | 169 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 2 | 2021 | 441 | 0.240 |
Why?
|
| Research Support as Topic | 2 | 2021 | 89 | 0.230 |
Why?
|
| History, 21st Century | 3 | 2021 | 187 | 0.230 |
Why?
|
| Bicarbonates | 1 | 2005 | 58 | 0.230 |
Why?
|
| History, 19th Century | 2 | 2021 | 53 | 0.230 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 762 | 0.230 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 443 | 0.230 |
Why?
|
| Doxorubicin | 5 | 2024 | 283 | 0.220 |
Why?
|
| Dogs | 4 | 2017 | 632 | 0.220 |
Why?
|
| Clotrimazole | 1 | 2004 | 3 | 0.220 |
Why?
|
| Charybdotoxin | 1 | 2004 | 8 | 0.220 |
Why?
|
| Splenic Artery | 1 | 2004 | 10 | 0.220 |
Why?
|
| Diarrhea | 1 | 2005 | 176 | 0.210 |
Why?
|
| Digestive System Abnormalities | 1 | 2004 | 11 | 0.210 |
Why?
|
| Wound Healing | 2 | 2004 | 372 | 0.210 |
Why?
|
| Thrombin | 1 | 2004 | 60 | 0.210 |
Why?
|
| Communicable Disease Control | 2 | 2022 | 55 | 0.210 |
Why?
|
| Aminopyridines | 1 | 2024 | 48 | 0.210 |
Why?
|
| Aneurysm, False | 1 | 2004 | 52 | 0.210 |
Why?
|
| Hemostatics | 1 | 2004 | 60 | 0.210 |
Why?
|
| Schools, Medical | 1 | 2005 | 131 | 0.200 |
Why?
|
| Peer Review, Research | 1 | 2024 | 37 | 0.200 |
Why?
|
| Pyrroles | 1 | 2024 | 165 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2024 | 135 | 0.200 |
Why?
|
| Paclitaxel | 5 | 2024 | 478 | 0.200 |
Why?
|
| Gastric Bypass | 1 | 2005 | 114 | 0.200 |
Why?
|
| Physics | 1 | 2003 | 21 | 0.200 |
Why?
|
| Transplantation | 1 | 2003 | 38 | 0.190 |
Why?
|
| Necrosis | 3 | 2012 | 203 | 0.190 |
Why?
|
| Stents | 3 | 2020 | 406 | 0.190 |
Why?
|
| Cyclophosphamide | 4 | 2024 | 278 | 0.190 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 2009 | 0.190 |
Why?
|
| Protein Transport | 5 | 2010 | 438 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 885 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2005 | 248 | 0.190 |
Why?
|
| Publishing | 1 | 2024 | 91 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 35 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2025 | 187 | 0.190 |
Why?
|
| Collagen | 1 | 2004 | 301 | 0.190 |
Why?
|
| Gastroenterology | 2 | 2016 | 157 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 392 | 0.180 |
Why?
|
| Regeneration | 1 | 2003 | 159 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 550 | 0.180 |
Why?
|
| Ion Channels | 1 | 2004 | 256 | 0.180 |
Why?
|
| Educational Measurement | 2 | 2021 | 236 | 0.180 |
Why?
|
| Tight Junctions | 1 | 2003 | 154 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 244 | 0.180 |
Why?
|
| Isoenzymes | 1 | 2002 | 271 | 0.180 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 272 | 0.180 |
Why?
|
| Biotinylation | 2 | 2012 | 42 | 0.170 |
Why?
|
| History, 15th Century | 1 | 2021 | 5 | 0.170 |
Why?
|
| History, 16th Century | 1 | 2021 | 8 | 0.170 |
Why?
|
| History, 17th Century | 1 | 2021 | 12 | 0.170 |
Why?
|
| History, Medieval | 1 | 2021 | 12 | 0.170 |
Why?
|
| History, 18th Century | 1 | 2021 | 20 | 0.170 |
Why?
|
| Reoperation | 2 | 2017 | 696 | 0.170 |
Why?
|
| Licensure, Medical | 1 | 2021 | 20 | 0.170 |
Why?
|
| Culturally Competent Care | 1 | 2021 | 13 | 0.170 |
Why?
|
| Human Rights | 1 | 2021 | 20 | 0.170 |
Why?
|
| History, Ancient | 1 | 2021 | 80 | 0.170 |
Why?
|
| Medicine | 1 | 2022 | 93 | 0.170 |
Why?
|
| Information Services | 1 | 2001 | 22 | 0.170 |
Why?
|
| Head Injuries, Penetrating | 1 | 2022 | 67 | 0.170 |
Why?
|
| Intestines | 1 | 2004 | 433 | 0.170 |
Why?
|
| Leadership | 2 | 2021 | 149 | 0.170 |
Why?
|
| Sex Factors | 2 | 2021 | 1102 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1786 | 0.170 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 119 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 1000 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 191 | 0.170 |
Why?
|
| Societies, Scientific | 1 | 2001 | 41 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1385 | 0.170 |
Why?
|
| Awards and Prizes | 1 | 2021 | 37 | 0.170 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 3814 | 0.160 |
Why?
|
| Risk | 2 | 2020 | 651 | 0.160 |
Why?
|
| Aged | 14 | 2024 | 20395 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2014 | 187 | 0.160 |
Why?
|
| Anastomosis, Roux-en-Y | 3 | 2012 | 26 | 0.160 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 3 | 2007 | 88 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2003 | 727 | 0.160 |
Why?
|
| Critical Illness | 1 | 2003 | 342 | 0.160 |
Why?
|
| Animals | 15 | 2017 | 27973 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 95 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 71 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2020 | 169 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 636 | 0.150 |
Why?
|
| Uncertainty | 1 | 2020 | 78 | 0.150 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2007 | 479 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 124 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 54 | 0.150 |
Why?
|
| Academic Medical Centers | 4 | 2022 | 396 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2021 | 106 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 1098 | 0.150 |
Why?
|
| Robotics | 1 | 2022 | 267 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 688 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 1236 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2011 | 199 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2020 | 137 | 0.140 |
Why?
|
| Quality of Life | 3 | 2017 | 1776 | 0.140 |
Why?
|
| Colforsin | 2 | 2012 | 68 | 0.140 |
Why?
|
| Students | 1 | 2020 | 177 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 320 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 163 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 188 | 0.140 |
Why?
|
| Health Status | 1 | 2020 | 373 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 2562 | 0.140 |
Why?
|
| Fasting | 1 | 2018 | 164 | 0.140 |
Why?
|
| Health Equity | 1 | 2020 | 101 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2012 | 774 | 0.130 |
Why?
|
| Internet | 1 | 2020 | 345 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 1980 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 389 | 0.130 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 148 | 0.130 |
Why?
|
| Contraindications | 2 | 2014 | 65 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 648 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 1908 | 0.120 |
Why?
|
| Personal Protective Equipment | 3 | 2021 | 38 | 0.120 |
Why?
|
| Sepsis | 2 | 2011 | 382 | 0.120 |
Why?
|
| Patient Readmission | 2 | 2017 | 403 | 0.120 |
Why?
|
| Cells, Cultured | 4 | 2005 | 2827 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 2016 | 102 | 0.110 |
Why?
|
| Abdominal Abscess | 1 | 2015 | 23 | 0.110 |
Why?
|
| Tissue Preservation | 1 | 2015 | 15 | 0.110 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 274 | 0.110 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 36 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2014 | 1518 | 0.110 |
Why?
|
| Sodium-Bicarbonate Symporters | 2 | 2005 | 8 | 0.110 |
Why?
|
| Child | 6 | 2022 | 7273 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2017 | 116 | 0.100 |
Why?
|
| Pancreatic Hormones | 1 | 2014 | 16 | 0.100 |
Why?
|
| Hypersensitivity | 3 | 2007 | 161 | 0.100 |
Why?
|
| Insulin | 4 | 2014 | 1184 | 0.100 |
Why?
|
| Calcium | 2 | 2012 | 1173 | 0.100 |
Why?
|
| Kidney | 3 | 2009 | 1093 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 1697 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 3 | 2011 | 435 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2016 | 373 | 0.100 |
Why?
|
| Camptothecin | 2 | 2024 | 195 | 0.100 |
Why?
|
| Endoscopy | 2 | 2017 | 366 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 54 | 0.100 |
Why?
|
| Risk Factors | 4 | 2017 | 5900 | 0.100 |
Why?
|
| Bryostatins | 2 | 2003 | 14 | 0.100 |
Why?
|
| Cell Polarity | 2 | 2005 | 118 | 0.100 |
Why?
|
| Macrolides | 2 | 2003 | 30 | 0.100 |
Why?
|
| California | 1 | 2013 | 157 | 0.100 |
Why?
|
| Time Factors | 4 | 2019 | 5380 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 93 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 160 | 0.090 |
Why?
|
| Diterpenes | 1 | 2012 | 24 | 0.090 |
Why?
|
| Acrylamides | 1 | 2012 | 34 | 0.090 |
Why?
|
| Electric Conductivity | 1 | 2012 | 142 | 0.090 |
Why?
|
| Research | 3 | 2003 | 250 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2012 | 58 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2017 | 1004 | 0.090 |
Why?
|
| Abscess | 1 | 2012 | 94 | 0.090 |
Why?
|
| Cell Membrane | 3 | 2005 | 661 | 0.090 |
Why?
|
| Survival Rate | 3 | 2021 | 1945 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2011 | 83 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2012 | 98 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2301 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2025 | 913 | 0.090 |
Why?
|
| Jejunum | 1 | 2012 | 76 | 0.090 |
Why?
|
| Acute Disease | 1 | 2014 | 838 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 638 | 0.090 |
Why?
|
| Duodenum | 1 | 2012 | 111 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 94 | 0.080 |
Why?
|
| Dopamine | 1 | 2012 | 276 | 0.080 |
Why?
|
| Debridement | 1 | 2011 | 59 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 371 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2011 | 69 | 0.080 |
Why?
|
| Laparoscopes | 1 | 2011 | 12 | 0.080 |
Why?
|
| Regional Health Planning | 1 | 2010 | 12 | 0.080 |
Why?
|
| Chronic Pain | 1 | 2013 | 187 | 0.080 |
Why?
|
| National Health Programs | 1 | 2010 | 18 | 0.080 |
Why?
|
| Cost Control | 1 | 2010 | 43 | 0.080 |
Why?
|
| Algorithms | 2 | 2012 | 1948 | 0.080 |
Why?
|
| Adolescent | 8 | 2019 | 9550 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 3431 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1188 | 0.080 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.080 |
Why?
|
| Cystadenoma, Serous | 1 | 2010 | 16 | 0.080 |
Why?
|
| Cystadenoma, Papillary | 1 | 2010 | 9 | 0.080 |
Why?
|
| Young Adult | 6 | 2021 | 6922 | 0.080 |
Why?
|
| Ions | 1 | 2010 | 74 | 0.080 |
Why?
|
| Polymers | 1 | 2011 | 217 | 0.080 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 33 | 0.080 |
Why?
|
| Financing, Government | 1 | 2010 | 24 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2011 | 311 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2007 | 379 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2005 | 3497 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 68 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2021 | 10128 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2009 | 41 | 0.080 |
Why?
|
| Membrane Microdomains | 1 | 2009 | 52 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2010 | 295 | 0.070 |
Why?
|
| RNA Interference | 1 | 2010 | 379 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2010 | 340 | 0.070 |
Why?
|
| Autoantigens | 1 | 2010 | 138 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 7039 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 2009 | 98 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2007 | 773 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 139 | 0.070 |
Why?
|
| Liver | 2 | 2012 | 1206 | 0.070 |
Why?
|
| Ileum | 1 | 2009 | 167 | 0.070 |
Why?
|
| Professional Autonomy | 2 | 2020 | 38 | 0.070 |
Why?
|
| Reference Values | 2 | 2011 | 603 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 237 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 347 | 0.070 |
Why?
|
| Chloride Channels | 2 | 2005 | 43 | 0.070 |
Why?
|
| Rubidium Radioisotopes | 1 | 2007 | 4 | 0.070 |
Why?
|
| Methylamines | 1 | 2007 | 6 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 72 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1910 | 0.070 |
Why?
|
| Biological Transport, Active | 1 | 2007 | 98 | 0.070 |
Why?
|
| Learning | 2 | 2021 | 289 | 0.070 |
Why?
|
| Jejunostomy | 1 | 2007 | 13 | 0.070 |
Why?
|
| Rats | 4 | 2009 | 4028 | 0.070 |
Why?
|
| Prognosis | 3 | 2021 | 3890 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 451 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 339 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 272 | 0.060 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 140 | 0.060 |
Why?
|
| Autoimmune Diseases | 2 | 2007 | 255 | 0.060 |
Why?
|
| Length of Stay | 2 | 2014 | 820 | 0.060 |
Why?
|
| Surgical Instruments | 2 | 2005 | 61 | 0.060 |
Why?
|
| Immunization | 1 | 2007 | 154 | 0.060 |
Why?
|
| Glucose | 1 | 2009 | 686 | 0.060 |
Why?
|
| Carbazoles | 2 | 2004 | 31 | 0.060 |
Why?
|
| Protein Kinase C-alpha | 2 | 2004 | 29 | 0.060 |
Why?
|
| Enterohepatic Circulation | 1 | 2005 | 3 | 0.060 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2005 | 5 | 0.060 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 17 | 0.060 |
Why?
|
| Antiporters | 1 | 2005 | 15 | 0.060 |
Why?
|
| Stilbenes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 833 | 0.060 |
Why?
|
| Biological Transport | 2 | 2004 | 398 | 0.060 |
Why?
|
| Membrane Potentials | 2 | 2004 | 404 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2005 | 239 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2005 | 125 | 0.060 |
Why?
|
| Autoimmunity | 2 | 2010 | 191 | 0.060 |
Why?
|
| Ohio | 1 | 2005 | 42 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 1171 | 0.060 |
Why?
|
| Age Factors | 1 | 2009 | 1898 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2004 | 1129 | 0.050 |
Why?
|
| Ischemic Preconditioning | 1 | 2005 | 37 | 0.050 |
Why?
|
| Myristoylated Alanine-Rich C Kinase Substrate | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cholinergic Agonists | 1 | 2004 | 11 | 0.050 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 36 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 21 | 0.050 |
Why?
|
| Barium | 1 | 2004 | 32 | 0.050 |
Why?
|
| Dissection | 1 | 2005 | 44 | 0.050 |
Why?
|
| Indoles | 2 | 2004 | 298 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 199 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2024 | 18 | 0.050 |
Why?
|
| Myosin Light Chains | 1 | 2003 | 25 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2004 | 32 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2005 | 137 | 0.050 |
Why?
|
| Salmonella typhimurium | 1 | 2004 | 32 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 429 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2025 | 144 | 0.050 |
Why?
|
| Mice | 3 | 2012 | 12230 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2705 | 0.050 |
Why?
|
| Chlorine | 1 | 2003 | 8 | 0.050 |
Why?
|
| Biliary Fistula | 1 | 2003 | 11 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 292 | 0.050 |
Why?
|
| Stimulation, Chemical | 1 | 2003 | 54 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2005 | 131 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2003 | 39 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2003 | 71 | 0.050 |
Why?
|
| Ultrasonics | 1 | 2003 | 36 | 0.050 |
Why?
|
| Quantum Theory | 1 | 2003 | 40 | 0.050 |
Why?
|
| Growth Substances | 1 | 2003 | 79 | 0.050 |
Why?
|
| Chimera | 1 | 2003 | 52 | 0.050 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2003 | 11 | 0.050 |
Why?
|
| Professional Practice | 1 | 2003 | 43 | 0.050 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 87 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1660 | 0.050 |
Why?
|
| Claudin-1 | 1 | 2003 | 17 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2003 | 66 | 0.050 |
Why?
|
| Occludin | 1 | 2003 | 66 | 0.050 |
Why?
|
| Tritium | 1 | 2002 | 113 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1054 | 0.050 |
Why?
|
| Ammonia | 1 | 2003 | 34 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2002 | 40 | 0.050 |
Why?
|
| Thapsigargin | 1 | 2002 | 55 | 0.050 |
Why?
|
| Mannitol | 1 | 2002 | 49 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1022 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 84 | 0.050 |
Why?
|
| Cell Membrane Permeability | 1 | 2003 | 121 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2016 | 278 | 0.050 |
Why?
|
| Potassium | 1 | 2003 | 224 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2003 | 115 | 0.050 |
Why?
|
| Epithelium | 1 | 2003 | 314 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 750 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 7 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 208 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 137 | 0.050 |
Why?
|
| Carcinogens | 1 | 2002 | 101 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 237 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 403 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2003 | 119 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 494 | 0.040 |
Why?
|
| Specialization | 1 | 2022 | 67 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 689 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 291 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2004 | 243 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2004 | 679 | 0.040 |
Why?
|
| Maytansine | 1 | 2021 | 16 | 0.040 |
Why?
|
| Governing Board | 1 | 2021 | 2 | 0.040 |
Why?
|
| Job Application | 1 | 2021 | 18 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 129 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2002 | 198 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2005 | 806 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 195 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2002 | 476 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 53 | 0.040 |
Why?
|
| Government Programs | 1 | 2000 | 8 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2003 | 424 | 0.040 |
Why?
|
| Cell Movement | 1 | 2004 | 804 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 68 | 0.040 |
Why?
|
| Bacterial Adhesion | 2 | 2011 | 83 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 16 | 0.040 |
Why?
|
| Social Problems | 1 | 2020 | 10 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 196 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 412 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1909 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 25 | 0.040 |
Why?
|
| Computer-Assisted Instruction | 1 | 2020 | 45 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 578 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 126 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 480 | 0.040 |
Why?
|
| Epidemics | 1 | 2020 | 41 | 0.040 |
Why?
|
| Virulence | 2 | 2011 | 273 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2022 | 297 | 0.040 |
Why?
|
| Piperazines | 1 | 2021 | 284 | 0.040 |
Why?
|
| Actins | 1 | 2002 | 467 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2003 | 416 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 161 | 0.040 |
Why?
|
| Hypoxia | 1 | 2004 | 672 | 0.040 |
Why?
|
| Cytokines | 1 | 2003 | 862 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 98 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 350 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 149 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 43 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 1054 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 42 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 465 | 0.040 |
Why?
|
| Violence | 1 | 2020 | 151 | 0.040 |
Why?
|
| C-Peptide | 1 | 2018 | 184 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 234 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 590 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 888 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 4546 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 878 | 0.030 |
Why?
|
| Hypoglycemic Agents | 2 | 2014 | 378 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 1517 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2001 | 295 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 40 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 364 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2020 | 343 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1905 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 178 | 0.030 |
Why?
|
| Asthma | 2 | 2001 | 1039 | 0.030 |
Why?
|
| Models, Biological | 1 | 2003 | 1768 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2016 | 22 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 180 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 268 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 312 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 280 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 359 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1849 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 603 | 0.030 |
Why?
|
| Apoptosis | 2 | 2011 | 1719 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 72 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 366 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2014 | 92 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 482 | 0.020 |
Why?
|
| Electrophysiology | 2 | 2004 | 389 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 204 | 0.020 |
Why?
|
| Hepatectomy | 2 | 2004 | 177 | 0.020 |
Why?
|
| Illinois | 1 | 2014 | 515 | 0.020 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 26 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2011 | 13 | 0.020 |
Why?
|
| Financial Support | 1 | 2011 | 7 | 0.020 |
Why?
|
| Phenols | 1 | 2011 | 41 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 125 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2011 | 70 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2005 | 941 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2011 | 46 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 50 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 161 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 308 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2011 | 56 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 354 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2011 | 258 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2010 | 762 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 174 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 219 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 279 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 874 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 2011 | 291 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 655 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 303 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 364 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 93 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 800 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1727 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 916 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 70 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2005 | 18 | 0.010 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2005 | 11 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 590 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 2005 | 138 | 0.010 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 60 | 0.010 |
Why?
|
| RNA, Complementary | 1 | 2004 | 8 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 618 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2479 | 0.010 |
Why?
|
| Phenylalanine | 1 | 2004 | 31 | 0.010 |
Why?
|
| Xenopus | 1 | 2004 | 119 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 118 | 0.010 |
Why?
|
| Oocytes | 1 | 2005 | 211 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1732 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 275 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1519 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 35 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 83 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 268 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 2003 | 34 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 672 | 0.010 |
Why?
|
| Stress Fibers | 1 | 2003 | 23 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 53 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 281 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 287 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2005 | 296 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 351 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 422 | 0.010 |
Why?
|
| Ion Transport | 1 | 2003 | 82 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 877 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 312 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 726 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2003 | 373 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 191 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 981 | 0.010 |
Why?
|
| Pain | 1 | 2003 | 412 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 515 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 653 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 1172 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1260 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 3044 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2000 | 871 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 4265 | 0.010 |
Why?
|